Pantoprazole Unifarma (Pantoprazole Sodium Sesquihydrate)

Pantoprazole Unifarma is a proton‑pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions:

• Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and promotes healing of erosive esophagitis.
• Erosive oesophagitis: heals mucosal breaks caused by chronic acid exposure.
• Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumours.
• Peptic ulcer disease (duodenal and gastric ulcers): supports ulcer healing and reduces recurrence risk.

• Pantoprazole selectively inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By binding covalently to the pump’s cysteine residues, it blocks the final step of acid secretion, leading to a sustained increase in gastric pH and reduction of gastric acidity.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhoea: usually self‑limiting.
• Nausea or vomiting: occasional gastrointestinal upset.
• Abdominal pain or flatulence: mild discomfort.
• Constipation: infrequent but reported.
• Dry mouth: transient sensation.

Serious or Rare Side Effects

• Acute interstitial nephritis: inflammation of kidney tissue.
• Severe allergic reactions: rash, angioedema, or anaphylaxis.
• Clostridioides difficile infection: associated with altered gut flora.
• Osteoporosis‑related fractures: long‑term use may affect bone density.
• Vitamin B12 deficiency: reduced absorption with chronic therapy.

Before initiating therapy, consider the following safety points:

• Assess renal function: dose adjustment may be required in severe impairment.
• Review concomitant medications: potential for reduced efficacy of drugs needing acidic pH.
• Monitor for infections: prolonged acid suppression can increase risk of gastrointestinal infections.
• Evaluate bone health: long‑term use may impact calcium absorption.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Pantoprazole may affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid)

• Ketoconazole or itraconazole: markedly reduced antifungal absorption.
• Atazanavir or nelfinavir: decreased antiviral exposure leading to therapeutic failure.

Moderate Interactions (Monitor Closely)

• Warfarin: potential increase in INR; monitor coagulation parameters.
• Digoxin: slight increase in serum levels; observe for toxicity signs.
• Methotrexate (high dose): reduced renal clearance; check serum concentrations.
• Mycophenolate mofetil: possible increase in exposure; adjust dose if needed.